Management of pulmonary hypertension in infants

References

• Steurer MA, Baer RJ, Oltman S, et al. Morbidity of persistent pulmonary hypertension of the newborn in the first year of life. J Pediatr. 2019;213:58–65.e4. Epub 2019/08/11. doi: 10.1016/j.jpeds.2019.06.053. PubMed PMID: 31399244.
   PubMed Web of Science ®Google Scholar
• Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 2000;105(1 Pt 1):14–20. Epub 2000/01/05. doi: 10.1542/peds.105.1.14. PubMed PMID: 10617698.
   PubMed Web of Science ®Google Scholar
• Lakshminrusimha S, Steinhorn RH. Pulmonary vascular biology during neonatal transition. Clin Perinatol. 1999;26(3):601–619. Epub 1999/09/24. PubMed PMID: 10494467. doi: 10.1016/S0095-5108(18)30039-3
   PubMed Web of Science ®Google Scholar
• Farrow KN, Lee KJ, Perez M, et al. Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells. Antioxid Redox Signal. 2012;17(3):460–470. Epub 2012/01/11. doi: 10.1089/ars.2011.4184 PubMed PMID: 22229392; PubMed Central PMCID: PMCPMC3365357.
   PubMed Web of Science ®Google Scholar
• Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment. Semin Perinatol. 2014;38(2):78–91. Epub 2014/03/04. doi: 10.1053/j.semperi.2013.11.004 PubMed PMID: 24580763; PubMed Central PMCID: PMCPMC3942674.
   PubMed Web of Science ®Google Scholar
• Mandell E, Kinsella JP, Abman SH. Persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2021;56(3):661–669. Epub 2020/09/16. doi: 10.1002/ppul.25073 PubMed PMID: 32930508.
   PubMed Web of Science ®Google Scholar
• Al-Ghanem G, Shah P, Thomas S, et al. Bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis. J Perinatol. 2017;37(4):414–419. Epub 2017/01/13. doi: 10.1038/jp.2016.250. PubMed PMID: 28079864.
   PubMed Web of Science ®Google Scholar
• Sheth S, Goto L, Bhandari V, et al. Factors associated with development of early and late pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. J Perinatol. 2020;40(1):138–148. Epub 2019/11/15. doi: 10.1038/s41372-019-0549-9 PubMed PMID: 31723236; PubMed Central PMCID: PMCPMC7223406.
   PubMed Web of Science ®Google Scholar
• Collaco JM, Romer LH, Stuart BD, et al. Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia. Pediatr Pulmonol. 2012;47(11):1042–1053. Epub 2012/07/11. doi: 10.1002/ppul.22609 PubMed PMID: 22777709; PubMed Central PMCID: PMCPMC3963167.
   PubMed Web of Science ®Google Scholar
• Thodika FMSA, Nanjundappa M, Dassios T, et al. Pulmonary hypertension in infants with bronchopulmonary dysplasia: risk factors, mortality and duration of hospitalisation. J Perinat Med. 2022;50(3):327–333. doi: 10.1515/jpm-2021-0366
   PubMed Web of Science ®Google Scholar
• Cookson MW, Abman SH, Kinsella JP, et al. Pulmonary vasodilator strategies in neonates with acute hypoxemic respiratory failure and pulmonary hypertension. Semin Fetal Neonatal Med. 2022;27(4):101367. Epub 2022/06/11. doi: 10.1016/j.siny.2022.101367 PubMed PMID: 35688685; PubMed Central PMCID: PMCPMC10329862.
   PubMed Web of Science ®Google Scholar
• Lotze A, Mitchell BR, Bulas DI, et al. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in term infants study group. J Pediatr. 1998;132(1):40–47. Epub 1998/02/21. doi: 10.1016/s0022-3476(98)70482-2 PubMed PMID: 9469998.
   PubMed Web of Science ®Google Scholar
• González A, Bancalari A, Osorio W, et al. Early use of combined exogenous surfactant and inhaled nitric oxide reduces treatment failure in persistent pulmonary hypertension of the newborn: a randomized controlled trial. J Perinatol. 2021;41(1):32–38. Epub 2020/08/15. doi: 10.1038/s41372-020-00777-x. PubMed PMID: 32792635.
   PubMed Web of Science ®Google Scholar
• Nelin LD, Potenziano JL. Inhaled nitric oxide for neonates with persistent pulmonary hypertension of the newborn in the CINRGI study: time to treatment response. BMC Pediatr. 2019;19(1):17. Epub 2019/01/15. doi: 10.1186/s12887-018-1368-4 PubMed PMID: 30636626; PubMed Central PMCID: PMCPMC6330425.
   PubMedGoogle Scholar
• Roberts JD Jr., Fineman JR, Morin FC 3rd, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The inhaled nitric oxide study group. N Engl J Med. 1997;336(9):605–610. Epub 1997/02/27. doi: 10.1056/nejm199702273360902 PubMed PMID: 9032045.
   PubMed Web of Science ®Google Scholar
• Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2006(4):Cd000399. Epub 2006/10/21. doi: 10.1002/14651858.CD000399.pub2 PubMed PMID: 17054129.
   Google Scholar
• Barrington KJ, Finer N, Pennaforte T, et al. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2017;1(1):Cd000399. Epub 2017/01/06. doi: 10.1002/14651858.CD000399.pub3 PubMed PMID: 28056166; PubMed Central PMCID: PMCPMC6464941 Committee for a single meeting, for which he received expenses and an honorarium. Dr Finer previously served as a member of the iNO Therapeutics Advisory Committee.
   PubMedGoogle Scholar
• Noh CY, Chock VY, Bhombal S, et al. Early nitric oxide is not associated with improved outcomes in congenital diaphragmatic hernia. Pediatr Res. 2023;93(7):1899–1906. Epub 2023/02/02. doi: 10.1038/s41390-023-02491-8 PubMed PMID: 36725908.
   PubMed Web of Science ®Google Scholar
• Lawrence KM, Monos S, Adams S, et al. Inhaled nitric oxide is associated with improved oxygenation in a subpopulation of infants with congenital diaphragmatic hernia and pulmonary hypertension. J Pediatr. 2020;219:167–172. Epub 2019/11/11. doi: 10.1016/j.jpeds.2019.09.052 PubMed PMID: 31706636.
   PubMed Web of Science ®Google Scholar
• Thodika F, Dimitrova S, Nanjundappa M, et al. Prediction of survival in infants with congenital diaphragmatic hernia and the response to inhaled nitric oxide. Eur J Pediatr. 2022;181(10):3683–3689. Epub 2022/07/29. doi: 10.1007/s00431-022-04568-8 PubMed PMID: 35900449; PubMed Central PMCID: PMCPMC9508000.
   PubMed Web of Science ®Google Scholar
• Maia PD, Gien J, Kinsella JP, et al. Hemodynamic characterization of neonates with congenital diaphragmatic hernia-associated pulmonary hypertension by cardiac catheterization. J Pediatr. 2023;255:230–5.e2. Epub 2022/12/05. doi: 10.1016/j.jpeds.2022.11.028 PubMed PMID: 36463937.
   PubMed Web of Science ®Google Scholar
• Greenough A. Management of infants with congenital diaphragmatic hernia and pulmonary hypertension-one size does not fit all. Pediatr Res. 2023;93(7):1795–1796. Epub 2023/03/03. doi: 10.1038/s41390-023-02551-z PubMed PMID: 36864283; PubMed Central PMCID: PMCPMC10313509.
   PubMed Web of Science ®Google Scholar
• Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2017;1(1):Cd000509. Epub 2017/01/04. doi: 10.1002/14651858.CD000509.pub5 PubMed PMID: 28045472; PubMed Central PMCID: PMCPMC6464861 therapeutics for one meeting in 2004. Dr Barrington and Dr Finer were participants in a research project funded by Ikaria, an individual patient data meta‐analysis of iNO in the preterm, from which neither received any income. Dr Barrington received an honorarium for speaking at a symposium funded by Mallinckrodt on the topic of probiotics.
   PubMedGoogle Scholar
• Clark RH, Ursprung RL, Walker MW, et al. The changing pattern of inhaled nitric oxide use in the neonatal intensive care unit. J Perinatol. 2010;30(12):800–804. Epub 2010/03/20. doi: 10.1038/jp.2010.37 PubMed PMID: 20237489.
   PubMed Web of Science ®Google Scholar
• Mercier JC, Hummler H, Durrmeyer X, et al. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. The Lancet. 2010;376(9738):346–354. Epub 2010/07/27. doi: 10.1016/s0140-6736(10)60664-2 PubMed PMID: 20655106.
   PubMed Web of Science ®Google Scholar
• Greenough A, Decobert F, Field D, et al. Inhaled nitric oxide (iNO) for preventing prematurity-related bronchopulmonary dysplasia (BPD): 7-year follow-up of the European Union nitric oxide (EUNO) trial. J Perinat Med. 2020;49(1):104–110. Epub 2020/09/07. doi: 10.1515/jpm-2020-0164 PubMed PMID: 32892178.
   PubMed Web of Science ®Google Scholar
• Han S, Crowther CA, Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev. 2010(7):Cd000940. Epub 2010/07/09. doi: 10.1002/14651858.CD000940.pub2 PubMed PMID: 20614423.
   Google Scholar
• Ho JJ, Rasa G. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev. 2007;2007(3):Cd005588. Epub 2007/07/20. doi: 10.1002/14651858.CD005588.pub2 PubMed PMID: 17636807; PubMed Central PMCID: PMCPMC8896076.
   PubMedGoogle Scholar
• Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 2009;155(6):841–7.e1. Epub 2009/10/20. doi: 10.1016/j.jpeds.2009.06.012 PubMed PMID: 19836028.
   PubMed Web of Science ®Google Scholar
• Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Systematic Rev. 2011(8). doi: 10.1002/14651858.CD005494.pub3 PubMed PMID: CD005494.
   PubMedGoogle Scholar
• He Z, Zhu S, Zhou K, et al. Sildenafil for pulmonary hypertension in neonates: an updated systematic review and meta-analysis. Pediatr Pulmonol. 2021;56(8):2399–2412. Epub 2021/05/14. doi: 10.1002/ppul.25444 PubMed PMID: 33983650.
   PubMed Web of Science ®Google Scholar
• Cochius-den Otter S, Schaible T, Greenough A, et al. The CoDiNOS trial protocol: an international randomised controlled trial of intravenous sildenafil versus inhaled nitric oxide for the treatment of pulmonary hypertension in neonates with congenital diaphragmatic hernia. BMJ Open. 2019;9(11):e032122. Epub 2019/11/07. doi: 10.1136/bmjopen-2019-032122 PubMed PMID: 31694851; PubMed Central PMCID: PMCPMC6858099.
   PubMed Web of Science ®Google Scholar
• Schroeder L, Monno P, Strizek B, et al. Intravenous sildenafil for treatment of early pulmonary hypertension in preterm infants. Scientific reports. 2023;13(1):8405. Epub 2023/05/25. doi: 10.1038/s41598-023-35387-y PubMed PMID: 37225769; PubMed Central PMCID: PMCPMC10209068 original work without fabrication, fraud, or plagiarism, and contains no libellous or unlawful statements. The manuscript is not under consideration for publication, nor will it be submitted for publication elsewhere, until a final decision has been made by this journal. As author I certify that each author has participated sufficiently in the work to take responsibility for its truthfulness and validity, has read the complete manuscript, and concurs with its content.
   Google Scholar
• Pierce CM, Zhang MH, Jonsson B, et al. Efficacy and safety of IV sildenafil in the treatment of newborn infants with, or at risk of, persistent pulmonary hypertension of the newborn (PPHN): a multicenter, randomized, placebo-controlled trial. J Pediatr. 2021;237:154–61.e3. Epub 2021/05/31. doi: 10.1016/j.jpeds.2021.05.051 PubMed PMID: 34052232.
   PubMed Web of Science ®Google Scholar
• Dillon K, Lamba V, Philip RR, et al. Efficacy of sildenafil in infants with bronchopulmonary dysplasia-associated pulmonary hypertension. Children (Basel). 2023;10(8). Epub 2023/08/26. doi: 10.3390/children10081397 PubMed PMID: 37628395; PubMed Central PMCID: PMCPMC10453183.
   PubMed Web of Science ®Google Scholar
• McNamara PJ, Laique F, Muang-In S, et al. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care. 2006;21(2):217–222. Epub 2006/06/14. doi: 10.1016/j.jcrc.2006.01.001 PubMed PMID: 16769471.
   PubMed Web of Science ®Google Scholar
• Bassler D, Choong K, McNamara P, et al. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate. 2006;89(1):1–5. Epub 2005/09/13. doi: 10.1159/000088192 PubMed PMID: 16155380.
   PubMedGoogle Scholar
• El-Khuffash A, McNamara PJ, Breatnach C, et al. The use of milrinone in neonates with persistent pulmonary hypertension of the newborn - a randomised controlled trial pilot study (MINT 1): study protocol and review of literature. Matern Health Neonatol Perinatol. 2018;4:24. Epub 2018/12/14. doi: 10.1186/s40748-018-0093-1 PubMed PMID: 30524749; PubMed Central PMCID: PMCPMC6276183.
   PubMedGoogle Scholar
• El-Ghandour M, Hammad B, Ghanem M, et al. Efficacy of milrinone plus sildenafil in the treatment of neonates with persistent pulmonary hypertension in resource-limited settings: results of a randomized, double-blind trial. Paediatr Drugs. 2020;22(6):685–693. Epub 2020/08/29. doi: 10.1007/s40272-020-00412-4 PubMed PMID: 32856285; PubMed Central PMCID: PMCPMC7453074 potential conflicts of interest that might be relevant to the contents of this manuscript.
   PubMed Web of Science ®Google Scholar
• Imam SS, Ra E-F, Taha AS, et al. Milrinone versus sildenafil in treatment of neonatal persistent pulmonary hypertension: a randomized control trial. J Cardiovasc Pharmacol. 2022;80(5):746–752. Epub 2022/07/27. doi: 10.1097/fjc.0000000000001332 PubMed PMID: 35881893.
   PubMed Web of Science ®Google Scholar
• Matsushita FY, Krebs VLJ, de Campos CV, et al. Reassessing the role of milrinone in the treatment of heart failure and pulmonary hypertension in neonates and children: a systematic review and meta-analysis. Eur J Pediatr. 2024;183(2):543–555. doi: 10.1007/s00431-023-05342-0
   PubMed Web of Science ®Google Scholar
• Jin H, Yang R, Chen Y, et al. Hemodynamic effects of arginine vasopressin in rats adapted to chronic hypoxia. J Appl Physiol. 1989;66(1):151–160. doi: 10.1152/jappl.1989.66.1.151
   PubMed Web of Science ®Google Scholar
• Evora PRB, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery: V1-receptor-mediated production of nitric oxide. Chest. 1993;103(4):1241–1245. doi: 10.1378/chest.103.4.1241
   PubMed Web of Science ®Google Scholar
• Budniok T, ElSayed Y, Louis D. Effect of vasopressin on systemic and pulmonary hemodynamics in neonates. Am J Perinatol. 2020;38(12):1330–1334. doi: 10.1055/s-0040-1712999
   PubMed Web of Science ®Google Scholar
• Capolupo I, De Rose DU, Mazzeo F, et al. Early vasopressin infusion improves oxygenation in infants with congenital diaphragmatic hernia. Front Pediatr. 2023:11. doi: 10.3389/fped.2023.1104728
   Web of Science ®Google Scholar
• More K, Athalye-Jape GK, Rao SC, et al. Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants. Cochrane Database Syst Rev. 2016;2016(8):Cd010531. Epub 2016/08/19. doi: 10.1002/14651858.CD010531.pub2 PubMed PMID: 27535894; PubMed Central PMCID: PMCPMC8588275 Sanjay Patole: none known.
   PubMedGoogle Scholar
• Maneenil G, Thatrimontrichai A, Janjindamai W, et al. Effect of bosentan therapy in persistent pulmonary hypertension of the newborn. Pediatr Neonatol. 2018;59(1):58–64. Epub 2017/07/25. doi: 10.1016/j.pedneo.2017.02.003 PubMed PMID: 28735030.
   PubMed Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70–75. Epub 1992/07/09. doi: 10.1056/nejm199207093270202 PubMed PMID: 1603138.
   PubMed Web of Science ®Google Scholar
• Eronen M, Pohjavuori M, Andersson S, et al. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol. 1997;18(1):3–7. Epub 1997/01/01. doi: 10.1007/s002469900099 PubMed PMID: 8960484.
   PubMed Web of Science ®Google Scholar
• Yıldırım Ş. Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns. Pulm Circ. 2023;13(3):e12268. Epub 2023/07/20. doi: 10.1002/pul2.12268 PubMed PMID: 37469523; PubMed Central PMCID: PMCPMC10352650.
   PubMed Web of Science ®Google Scholar
• Okbay Gunes A, Ciftel M, Timur ME, et al. Efficacy and safety of endotracheal instillation of iloprost for persistent pulmonary hypertension of the newborn. Cardiol Young. 2022;32(12):1894–1900. Epub 2022/01/07. doi: 10.1017/s1047951121005072 PubMed PMID: 34986915.
   PubMed Web of Science ®Google Scholar
• Verma S, Lumba R, Kazmi SH, et al. Effects of inhaled iloprost for the management of persistent pulmonary hypertension of the newborn. Am J Perinatol. 2022;39(13):1441–1448. Epub 2021/01/22. doi: 10.1055/s-0040-1722653 PubMed PMID: 33477175.
   PubMed Web of Science ®Google Scholar
• De Bie FR, Avitabile CM, Flohr S, et al. Treprostinil in neonates with congenital diaphragmatic hernia-related pulmonary hypertension. J Pediatr. 2023;259:113420. Epub 2023/04/15. doi: 10.1016/j.jpeds.2023.113420 PubMed PMID: 37059388.
   PubMed Web of Science ®Google Scholar
• Stasch J-P, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263–2273. doi: 10.1161/CIRCULATIONAHA.110.981738
   PubMed Web of Science ®Google Scholar
• Lian T-Y, Jiang X, Jing Z-C. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Des Devel Ther. 2017;11:1195–1207. doi: 10.2147/DDDT.S117277
   PubMed Web of Science ®Google Scholar
• Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–340. doi: 10.1056/NEJMoa1209655
   PubMed Web of Science ®Google Scholar
• Domingo LT, Ivy DD, Abman SH, et al. Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide. Front Pediatr. 2022;10:1014922. Epub 2022/12/20. doi: 10.3389/fped.2022.1014922 PubMed PMID: 36533232; PubMed Central PMCID: PMCPMC9751701.
   PubMed Web of Science ®Google Scholar
• Giesinger RE, Stanford AH, Thomas B, et al. Safety and feasibility of riociguat therapy for the treatment of chronic pulmonary arterial hypertension in infancy. J Pediatr. 2023;255:224–9.e1. doi: 10.1016/j.jpeds.2022.11.026
   PubMed Web of Science ®Google Scholar
• Ruoss JL, Moronta SC, Bazacliu C, et al. Management of cardiac dysfunction in neonates with pulmonary hypertension and the role of the ductus arteriosus. Semin Fetal Neonatal Med. 2022;27(4):101368. doi: 10.1016/j.siny.2022.101368
   PubMed Web of Science ®Google Scholar
• Tsoi SM, Nawaytou H, Almeneisi H, et al. Prostaglandin-E1 infusion in persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2024;59(2):379–388. doi: 10.1002/ppul.26759
   PubMed Web of Science ®Google Scholar
• Hari Gopal S, Patel N, Fernandes CJ. Use of prostaglandin E1 in the management of congenital diaphragmatic hernia-A review. Front Pediatr. 2022;10:911588. Epub 2022/07/19. doi: 10.3389/fped.2022.911588 PubMed PMID: 35844758; PubMed Central PMCID: PMCPMC9283565.
   PubMed Web of Science ®Google Scholar
• Shiyanagi S, Okazaki T, Shoji H, et al. Management of pulmonary hypertension in congenital diaphragmatic hernia: nitric oxide with prostaglandin-E1 versus nitric oxide alone. Pediatr Surg Int. 2008;24(10):1101–1104. doi: 10.1007/s00383-008-2225-6
   PubMed Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1). Epub 2022/08/27. doi: 10.1183/13993003.00879-2022 PubMed PMID: 36028254.
   Web of Science ®Google Scholar
• Zhu F, Ibarra Rios D, Joye S, et al. Cardiopulmonary physiological effects of diuretic therapy in preterm infants with chronic pulmonary hypertension. J Perinatol. 2023;43(10):1288–1294. doi: 10.1038/s41372-023-01742-0 PubMed PMID: 37550529.
   PubMed Web of Science ®Google Scholar